申请人:Vela Pharmaceuticals, Inc.
公开号:US20040254174A1
公开(公告)日:2004-12-16
(R)-tofisopam, substantially free of the (S)-enantiomer of tofisopam, is obtained by separating the enantiomers of tofisopam by chromatography employing a chiral separation medium comprising (i) (2S)-2-{(1S)[(3,5-dinitrophenyl)carbonylamino]phenylmethyl}-3,3-dimethylbutanoate, covalently bound to silica through an alkylene ester linkage or (ii) an amylose derivative of formula I:
1
wherein each R
1
and n are defined herein; the amylose derivative being coated on a porous inorganic carrier or a porous organic carrier.
(R)-托非索帕姆,基本上不含托非索帕姆的(S)-对映体,是通过利用手性分离介质进行色谱分离托非索帕姆的对映体而得到的,该手性分离介质包括(i) (2S)-2-(1S)-[(3,5-二硝基苯基)羰基氨基]苯甲基}-3,3-二甲基丁酸丁酯,通过烷基酯键结合到硅胶上,或(ii) 公式I:1的一种糖苷衍生物,其中每个R1和n在此定义;该糖苷衍生物被涂覆在多孔无机载体或多孔有机载体上。